• Mashup Score: 98
    Program Guide – ASCO Meeting Program Guide - 16 day(s) ago

    Shilpa Gupta Cleveland Clinic Taussig Cancer Institute, Cleveland, OH Shilpa Gupta, Jens Bedke, Michiel Van Der Heijden, Begoña Valderrama, Eiji Kikuchi, Jeannie Hoffman-Censits, Gopa Iyer, Christof Vulsteke, Steffen Rausch, Se Hoon Park, Alexandra Drakaki, Waddah Arafat, Umang Swami, Ignacio Duran, Jian-Ri Li, Blanca Homet Moreno, Seema Gorla, Xuesong Yu, Yi-Tsung Lu, Thomas Powles Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Department of Urology & Eva Mayr-Stihl Cancer Center, Stuttgart,

    Source: meetings.asco.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of neerajaiims
      neerajaiims

      Congrats @shilpaonc for oral ab#4502 @ASCO #ASCO25👉https://t.co/dtFXREYI6n👉In the Ph3 EV-302 trial in mUC #bladdercancer, pts achieving a CR had higher PFS & OS w/ EV+P vs. chemo (exploratory analysis)👇@umangtalking @OncoAlert @urotoday @Uromigos @BladderCancerUS @tompowles1 https://t.co/nr2PWrPZ1e

  • Mashup Score: 83
    Program Guide – ASCO Meeting Program Guide - 17 day(s) ago

    David Olmos Hospital Universitario 12 de Octubre. Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain David Olmos, David Lorente, Ana Jambrina, Daniel Tello Velasco, Ignacio Gonzalez Ginel, Nuria Romero-Laorden, Diogo Nunes Carneiro, Maria Ovejero Sánchez, Jordi Miguel, Fernando Alberca del Arco, Daniel Pérez-Argüelles, Alexandra Jürgens, Camille Capone, Marco Trevisan, Suzy Van Sanden, Gabriel Stulnig, Alfredo Rodríguez Antolín, Daniel Castellano, Bernardo Herrera Imbroda, Elena

    Source: meetings.asco.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of neerajaiims
      neerajaiims

      Ab#5094 @ASCO #ASCO25 by @Dolmos77👉https://t.co/Cy3vicrS1C👉Impact of BRCA and HRR alt in pts w/ mHSPC #prostatecancer 👉Pts w/ BRCA alt have worse survival regardless of disease volume or treatment received👇@Ecastromarcos @OncoAlert @urotoday @PCF_Science https://t.co/7SqSWOeb6w

  • Mashup Score: 83
    Program Guide – ASCO Meeting Program Guide - 17 day(s) ago

    David Olmos Hospital Universitario 12 de Octubre. Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain David Olmos, David Lorente, Ana Jambrina, Daniel Tello Velasco, Ignacio Gonzalez Ginel, Nuria Romero-Laorden, Diogo Nunes Carneiro, Maria Ovejero Sánchez, Jordi Miguel, Fernando Alberca del Arco, Daniel Pérez-Argüelles, Alexandra Jürgens, Camille Capone, Marco Trevisan, Suzy Van Sanden, Gabriel Stulnig, Alfredo Rodríguez Antolín, Daniel Castellano, Bernardo Herrera Imbroda, Elena

    Source: meetings.asco.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of neerajaiims
      neerajaiims

      Ab#5094 @ASCO #ASCO25 by @Dolmos77👉https://t.co/Cy3vicrS1C👉Impact of BRCA and HRR alt in pts w/ mHSPC #prostatecancer 👉Pts w/ BRCA alt have worse survival regardless of disease volume or treatment received👇@Ecastromarcos @OncoAlert @urotoday @PCF_Science https://t.co/7SqSWOeb6w

  • Mashup Score: 50
    Program Guide – ASCO Meeting Program Guide - 17 day(s) ago

    Praful Ravi Dana-Farber Cancer Institute, Boston, MA Praful Ravi, Lucia Kwak, Wanling Xie, Anthony D’Amico, James Dignam, Karim Fizazi, Nicholas James, Gwenael Le Teuff, Paul Nguyen, Howard Sandler, Alton Sartor, Matthew Sydes, Christopher Sweeney Dana-Farber Cancer Institute, Boston, MA, Brigham and Women’s Hospital, Boston, MA, University of Chicago, Chicago, IL, Institut Gustave Roussy, University of Paris -Saclay, Villejuif, France, The Institute of Cancer Research and The Royal Marsden Hospital NHS

    Source: meetings.asco.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of neerajaiims
      neerajaiims

      Congrats @PrafulRavi1 for rapid-oral (Ab#5013) @ASCO #ASCO25 👉https://t.co/zY7qMtWC7h 👉Analysis of pt-level data of trials of docetaxel+RT+ADT in pts w/ high-risk localized #prostatecancer (ICECaP)👉Some benefit w/ docetaxel👇@ChrisSweens1 @OncoAlert @urotoday @PCF_Science https://t.co/omTntxPSCg

  • Mashup Score: 83
    Program Guide – ASCO Meeting Program Guide - 17 day(s) ago

    Charles Parker University College London Cancer Institute, London, United Kingdom Charles Parker, Vinnie Liu, Larissa Mendes, Emily Grist, Rikiya Yamashita, Danielle Croucher, Ashwin Sachdeva, Laura Murphy, Huei-Chung Huang, Robert Jones, Silke Gillessen, Chris Parker, Daniel Berney, Phuoc Tran, Daniel Spratt, Mahesh Parmar, Noel Clarke, Louise Brown, Nicholas James, Gerhardt Attard University College London Cancer Institute, London, United Kingdom, Artera, Los Altos, CA, The Christie and Salford Royal

    Source: meetings.asco.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of neerajaiims
      neerajaiims

      Ab#5001 @ASCO #ASCO25 by #CharlesParker👉https://t.co/LTu80TrYFj👉Multimodal AI model (MMAI) in pts w/ high-risk nmPC #prostatecancer 👉MMAI can identify pts benefit from the addition of ARPI 👇 @Prof_Nick_James @AttardLab @OncoAlert @urotoday @PCF_Science https://t.co/kdu5Kvug2V

  • Mashup Score: 83
    Program Guide – ASCO Meeting Program Guide - 18 day(s) ago

    Charles Parker University College London Cancer Institute, London, United Kingdom Charles Parker, Vinnie Liu, Larissa Mendes, Emily Grist, Rikiya Yamashita, Danielle Croucher, Ashwin Sachdeva, Laura Murphy, Huei-Chung Huang, Robert Jones, Silke Gillessen, Chris Parker, Daniel Berney, Phuoc Tran, Daniel Spratt, Mahesh Parmar, Noel Clarke, Louise Brown, Nicholas James, Gerhardt Attard University College London Cancer Institute, London, United Kingdom, Artera, Los Altos, CA, The Christie and Salford Royal

    Source: meetings.asco.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of neerajaiims
      neerajaiims

      Ab#5001 @ASCO #ASCO25 by #CharlesParker👉https://t.co/LTu80TrYFj👉Multimodal AI model (MMAI) in pts w/ high-risk nmPC #prostatecancer 👉MMAI can identify pts benefit from the addition of ARPI 👇 @Prof_Nick_James @AttardLab @OncoAlert @urotoday @PCF_Science https://t.co/kdu5Kvug2V

  • Mashup Score: 79
    Program Guide – ASCO Meeting Program Guide - 18 day(s) ago

    Tian Zhang Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Dallas, TX Tian Zhang, Karla Ballman, Bradley McGregor, Helen Moon, Marc Matrana, Robert Alter, Abhishek Tripathi, Yuanquan Yang, Rana McKay, Deepak Kilari, Ulka Vaishampayan, Hamid Emamekhoo, Elaine Lam, Suzanne Cole, Tracy Rose, Stephanie Berg, Alan Tan, Michael Morris, Daniel George, Toni Choueiri Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern, Dallas, TX, Mayo

    Source: meetings.asco.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of neerajaiims
      neerajaiims

      Ab#4516 @ASCO #ASCO25 by @TiansterZhang 👉https://t.co/WknBTgSbJ8👉@ALLIANCE_org Ph 3 PDIGREE trial 👉 ipi-nivo induction (f/ued by nivo, cabo or nivo-cabo in mccRCC #kidneycancer 👉Initial outcomes with induction ipi-nivo👇@DrChoueiri @OncoAlert @urotoday @KidneyCAN https://t.co/7KwlAk4Re6

  • Mashup Score: 94
    Program Guide – ASCO Meeting Program Guide - 21 day(s) ago

    Michael Ong The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada Michael Ong, Soumyajit Roy, Kim Chi, Tanya Dorff, Sebastien Hotte, Alexander Wyatt, Lauren Howard, Karen Autio, Deborah Enting, Aurelius Omlin, Joaquin Mateo, Raymond McDermott, Ian Davis, Anders Bjartell, Laurel Cannon, Alyssa Chan-Cuzydlo, Philip Kantoff, Lorelei Mucci, Daniel George The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada, Rush University Medical Center, Chicago, IL, University of British Columbia, BC Cancer, Vancouver

    Source: meetings.asco.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of neerajaiims
      neerajaiims

      Congrats #MichaelOng @Soum_Roy_RadOnc for oral Ab#5002 @ASCO #ASCO25👉https://t.co/GfN567lIqZ👉Real-world IRONMAN registry of mHSPC #prostatecancer (n=1288 pts)👉PSA<0.02 after 6-12 mo of Rx had best prognosis (3-yr OS 92.7%)👇@Daniel_J_George @OncoAlert @urotoday @PCF_Science https://t.co/etMBMAU5uW

  • Mashup Score: 110
    Program Guide – ASCO Meeting Program Guide - 24 day(s) ago

    Toni Choueiri Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA Toni Choueiri, Bernard Escudier, David McDermott, Mauricio Burotto, Hans Hammers, Elizabeth Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Michael Atkins, Christian Kollmannsberger, Marc-Oliver Grimm, Yoshihiko Tomita, Brian Rini, Ruiyun Jiang, Maximiliano van Kooten Losio, Chung-Wei Lee, Robert Motzer, Nizar Tannir Lank Center for

    Source: meetings.asco.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of neerajaiims
      neerajaiims

      Ab#4505 @ASCO #ASCO25 by @DrChoueiri👉https://t.co/mO13Ibs7Cd👉9-year follow up of Checkmate 214 #kidneycancer👉Remarkable improvement in PFS & OS w/ IPI+NIVO in pts w/ RCC, no new safety signals👇#NizarTannir @OncoAlert @urotoday @KidneyCAN @KidneyCancer https://t.co/bEC8afiDYc

  • Mashup Score: 51
    Program Guide – ASCO Meeting Program Guide - 24 day(s) ago

    Zachary Yochum Yale Cancer Center, New Haven, CT Zachary Yochum, Renee Maria Saliby, Wanling Xie, Vivien Moritz, Connor Wells, Evan Ferrier, Martin Zarba, Hedyeh Ebrahimi, Cristina Suárez, Jose Ruiz-Morales, Rana McKay, Thomas Powles, Lori Wood, Aly-Khan Lalani, Sumanta Pal, Kosuke Takemura, Neeraj Agarwal, Daniel Heng, Toni Choueiri, Guillermo de Velasco Yale Cancer Center, New Haven, CT, Dana-Farber Cancer Institute, Boston, MA, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Barts Cancer

    Source: meetings.asco.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of neerajaiims
      neerajaiims

      Ab#4528 @ASCO #ASCO25 by #ZacharyYochum👉https://t.co/VBgkqDmdeD👉6-month TTF is predictive of 18-month OS in pts w/ mRCC receiving ICIs #kidneycancer 👉6-month TTF may be a promising intermediate endpoint for OS👇@DrDanielHeng @DrChoueiri @OncoAlert @urotoday @KidneyCAN https://t.co/eMXNEEyyzD

Load More